Get started
Author

Kelly Wright

Observed name: Wright, Kelly
ORCID: 0000-0003-2908-2612
Observed ORCID: 0000-0003-2908-2612
OpenAlex ID: A5072370749
Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance
2022 · Kerry L. LaPlante, Abhay Dhand, et al. · Annals of Medicine · 167
PDF
Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: a post-hoc analysis of the phase 3 OPTIC trial
2023 · George D. Rodriguez, Nathan Warren, et al. · Frontiers in Medicine · 8
PDF
1688. Omadacycline in Female Adults With Cystitis: Results From a Randomized, Double-Blinded, Adaptive Phase 2 Study
2020 · J Scott Overcash, Evan Tzanis, et al. · Open Forum Infectious Diseases · 5
PDF
1687. Omadacycline in Female Adults With Acute Pyelonephritis: Results from a Randomized, Double-Blind, Adaptive Phase 2 Study
2020 · J Scott Overcash, Evan Tzanis, et al. · Open Forum Infectious Diseases · 4
Intravenous Versus Oral Omadacycline or Linezolid for Acute Bacterial Skin and Skin Infections: A post hoc Analysis of the OASIS Trials
2024 · George D. Rodriguez, Nathan Warren, et al. · Infectious Diseases and Therapy · 3
PDF
Potential Cost Savings Associated with Targeted Substitution of Current Guideline-Concordant Inpatient Agents with Omadacycline for the Treatment of Adult Hospitalized Patients with Community-Acquired Bacterial Pneumonia at High Risk for Clostridioides difficile Infections: Results of Healthcare-Decision Analytic Model from the United States Hospital Perspective
2021 · Thomas Lodise, Mauricio Rodriguez, et al. · Antibiotics · 3
PDF
Re-evaluation of penicillin and ceftriaxone MIC results to predict susceptibility to the oral cephalosporin, cefpodoxime, in Streptococcus pneumoniae clinical isolates from the United States according to CLSI guidelines (2019–2021)
2025 · Rodrigo E. Mendes, Jessica V. Pierce, et al. · Journal of Clinical Microbiology · 2
Omadacycline powder for research procured from unauthorized commercial vendors may be impure and/or unstable
2024 · Alisa W. Serio, Daniel H. Deck, et al. · Antimicrobial Agents and Chemotherapy · 2
Activity of omadacycline in vitro against Clostridioides difficile and preliminary efficacy assessment in a hamster model of C. difficile-associated diarrhoea
2022 · Raina Gay Leahy, Alisa W. Serio, et al. · Journal of Global Antimicrobial Resistance · 2
PDF
Pathogens susceptible to tetracycline are also susceptible to omadacycline: tetracycline as a one-sided surrogate to predict omadacycline susceptible pathogens
2022 · Alisa W. Serio, Tiffany R. Keepers, et al. · Diagnostic Microbiology and Infectious Disease · 1
PDF
Prepared omadacycline for injection: Nine-day stability and sterility in an elastomeric pump
2022 · Jason Bower, Kelly Wright, et al. · SAGE Open Medicine · 1
Sub-growth-inhibitory concentrations of omadacycline inhibit Staphylococcus aureus haemolytic activity in vitro
2021 · Alisa W Serio, S Ken Tanaka, et al. · JAC-Antimicrobial Resistance · 1
1202. Subinhibitory Concentrations of Omadacycline Inhibit Staphylococcus aureus Hemolytic Activity in Vitro
2020 · Alisa W Serio, S Ken Tanaka, et al. · Open Forum Infectious Diseases · 1
PDF
P-411. Activity of Omadacycline Against 35,000 Bacterial Clinical Isolates and Resistant Organism Subsets from Patients in the United States (2019–2023)
2025 · Michael D Huband, Kelley A Fedler, et al. · Open Forum Infectious Diseases
1492. Targeted Substitution of Omadacycline in Place of Standard of Care for CABP Treatment is Associated with a Risk Reduction of Clostridioides difficile Infection and Financial Cost Savings in the Acute Care Setting
2020 · Mauricio Rodriguez, Surya Chitra, et al. · Open Forum Infectious Diseases
PDF
Works count: 16
Citation count: 200
H-index: 4
I10-index: 1
Year
Topic
Type